Fund+ Makes Moves In Europe With Further Growth On The Cards
VC Playbook: Exploring Fund+
Executive Summary
In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.
You may also be interested in...
ExeVir Bio Looks To Llamas To Tackle Coronavirus Crisis
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
Spanish Oncology Start-Up Ona Raises €30m
A syndicate of high-profile investors are backing the Barcelona-based firm's bid to develop biologics targeting metastatic-initiating cells and lipid metabolism.
VC View: Deal-Making During A Pandemic And 2021 Expectations
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Need a specific report? 1000+ reports available
Buy Reports